Orphan drug.

A drug developed for a rare disease under special regulatory incentives.

An orphan drug is one developed to treat a rare condition, formally defined by patient-population thresholds that differ by jurisdiction. Because such small markets would not normally repay development costs, regulators offer incentives including fee reductions, development assistance, and a period of market exclusivity once approved. Orphan designation is granted early, on the basis that the condition qualifies and the compound is plausible, and it is important to understand that designation is not approval: a designated compound has not been shown to work, and many never reach the market. Several peptide-based products have travelled this route, particularly in endocrine and metabolic rare diseases where a hormone pathway is clearly implicated. The relevance to general peptide reading is twofold. Orphan status is sometimes cited in promotional material as though it were a regulatory endorsement, which it is not. And a drug approved for a rare condition has been evaluated in that specific population for that specific indication, often in small trials, which does not establish that it is appropriate or safe for the much larger population of people who might want it for an adjacent reason. The evidence attaches to the studied indication, not to the molecule in general.